Glaxo zanamivir for flu prevention is possible switch candidate, firm tells analysts.
This article was originally published in The Tan Sheet
Executive Summary
GLAXO ZANAMIVIR FOR INFLUENZA PREVENTION VIEWED AS POTENTIAL SWITCH CANDIDATE, acting Head of Internal Medical Affairs Rick Fuller, MD, told securities analysts at a company R&D update in New York City May 5. Glaxo Wellcome is conducting separate trials of the inhaled neuraminidase inhibitor zanamivir for both treatment and prophylaxis of influenza.